Our Team
We are a mission-aligned team with expertise across human biology, immunology, chemistry, computational biology, data science, machine learning, drug development, clinical, and commercial leadership.
Our Purpose
We are drawn together by our shared purpose and relentless hunger to improve health outcomes for as many people as possible while reducing the growing chronic disease burden. Our approach to innovation is uniquely human-centered — unlocking connections between Anthromolecule™ chemistry and biological pathways driving disease to create solutions preferred by patients and clinicians that are designed to transform the treatment of disease.
We have brought together an inclusive, interdependently ambitious, and high-performing team with the courage to learn, iterate and make leaps together. We approach our work with humility, acknowledging and embracing the complexity of the disciplines we need to bring together and the many unknowns in human biology.
Leadership
Board of Directors
Our Advisors
-
Peter Hutt
Former Chief Counsel, FDA; Senior Counsel, Covington & Burlington LLP; Member, National Academy of Medicine -
Jim Karkanias, Ph.D.
CTO, Chan Zuckerberg Biohub; Former GM, Data Platform Group, Microsoft; Former Executive Director, Merck -
Iain McInnes, Ph.D., M.B.Ch.B
Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow -
Paul Navarre
Chairman, HTL; Chairman, Arkopharma; Board Member, LEO Pharma; Former CEO, Ferring Pharmaceuticals; Former President of International Operations and EAME, Allergan -
Jose Ordovas, Ph.D.
Professor and Leader of the Nutrition and Genomics Team at USDA Human Nutrition Research Center on Aging, Tufts University -
Paul Ridker, M.D.
Professor of Medicine, Harvard University and Brigham and Women's Hospital; Expert in inflammation and cardiovascular disease; Pioneered clinical research proving inflammation hypothesis in atherosclerosis, coronary artery disease, and more -
Luciano Rosetti, M.D.
CMO, Flagship Pioneering; Head of R&D, Pioneering Medicines; Former Global Head of R&D, Merck KGaA and Merck & Co. -
Luisa Salter-Cid, Ph.D.
CSO, Pioneering Medicines; Former CSO at Gossamer Bio; Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery, BMS -
Peter Sorger, Ph.D.
Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals -
Pietro Antonio Tataranni, M.D.
Chief Medical Officer, PepsiCo; Former SVP, Head of Medical Affairs, Diabetes and Cardiovascular, Sanofi -
Jing-Ke Weng, Ph.D.
Co-Founder, Double Rainbow Biosciences; Associate Professor of Biology, MIT; Member, Whitehead Institute for Biomedical Research
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com